Phase II study of hexamethylmelamine (NSC 13875)

Two hundred fifty-seven patients were evaluated in a phase II study of Hexamethylmelamine. The toxicity was essentially that observed in the phase I study, gastrointestinal toxicity in 54% and hematopoietic toxicity in 27%. Responses were noted primarily in carcinoma of the ovary and lung and more particularly oat cell and adenocarcinomas of the lung. The authors feel that this response rate is such that further studies, particularly in carcinoma of the lung, with hexamethylmelamine should be done.